Literature DB >> 21338954

Validity of two rapid point of care influenza tests and direct fluorecence assay in comparison of real time PCR for swine of origin Influenza virus.

S M Al Johani1, M Al Balawi, B Al Alwan, R Al Hefdhi, A Hajeer.   

Abstract

BACKGROUND: A novel swine origin influenza virus (S-OIV) is continue to spread worldwide and a global declaration of 2009 influenza pandemic was made by World Health Organization (WHO) June 2009, this along with approaching the winter season at the northern hemisphere, increase the interest to provide a quick, easy, affordable and available point of care testing for S-OIV.
OBJECTIVES: To determine the performance of two rapid point-of-care (POC) tests for influenza virus as well as direct fluorescence assay for the detection of the recently emerged a novel swine origin influenza virus (S-OIV). STUDY
DESIGN: A total of 143 respiratory samples which was submitted to Pathology and Laboratory Medicine at King AbdulAziz Medical City in Riyadh, Saudi Arabia from June 6th 2009 till June 28th 2009. All samples were tested in parallel using two rapid assays (BD Directigen EZ Flu®) and (TruFlu, Meridian®) as well as (Imagen Flu A/B DFA, Oxoid®) and compare it with RT-PCR. Each test's performed by different team, who were blinded for other team's result. Data gathered and we analyzed the analytical validity of each test.
RESULTS: The analytical sensitivity of the two influenza antigen detection tests for S-OIV was very low in comparison with RT-PCR, BD Directigen EZ performance was better than TruFlu test with sensitivities of 20.6% and 9.7% respectively. DFA perform much better than POC tests with sensitivity of 32.35%, specificity of 99.08% and PPV, NPV of 90% and 81.20% respectively.
CONCLUSION: The analytical sensitivity of the selected influenza A antigen detection tests for detection of S-OIV was very low, and should not be used to exclude S-OIV, DFA may be used as first line test especially during after hours or weekends, but negative results must confirmed by RT-PCR. Crown
Copyright © 2010. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21338954     DOI: 10.1016/j.jiph.2010.10.004

Source DB:  PubMed          Journal:  J Infect Public Health        ISSN: 1876-0341            Impact factor:   3.718


  8 in total

1.  Influenza A virus isolation, culture and identification.

Authors:  Amie J Eisfeld; Gabriele Neumann; Yoshihiro Kawaoka
Journal:  Nat Protoc       Date:  2014-10-16       Impact factor: 13.491

2.  Are Rapid Influenza Antigen Tests Still Clinically Useful in Today's Molecular Diagnostics World?

Authors:  Valentina K Trombetta; Yvonne L Chan; Matthew J Bankowski
Journal:  Hawaii J Med Public Health       Date:  2018-09

Review 3.  Tools to detect influenza virus.

Authors:  Dae-Ki Kim; Barun Poudel
Journal:  Yonsei Med J       Date:  2013-05-01       Impact factor: 2.759

4.  Evaluation of the Becton Dickinson Rapid Influenza Diagnostic Tests in Outpatients in Germany during Seven Influenza Seasons.

Authors:  Maren Eggers; Martin Enders; Elena Terletskaia-Ladwig
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

Review 5.  PCR for detection of respiratory viruses: seasonal variations of virus infections.

Authors:  Sigvard Olofsson; Robin Brittain-Long; Lars Magnus Andersson; Johan Westin; Magnus Lindh
Journal:  Expert Rev Anti Infect Ther       Date:  2011-08       Impact factor: 5.091

Review 6.  Point-of-care diagnostics for respiratory viral infections.

Authors:  Kerri Basile; Jen Kok; Dominic E Dwyer
Journal:  Expert Rev Mol Diagn       Date:  2017-12-26       Impact factor: 5.225

7.  Detection methods for influenza A H1N1 virus with special reference to biosensors: a review.

Authors:  Ravina R; Anita Dalal; Hari Mohan; Minakshi Prasad; C S Pundir
Journal:  Biosci Rep       Date:  2020-02-28       Impact factor: 3.840

Review 8.  COVID-19 Clinical Diagnostics and Testing Technology.

Authors:  Cindy H Chau; Jonathan D Strope; William D Figg
Journal:  Pharmacotherapy       Date:  2020-08       Impact factor: 6.251

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.